These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31813444)

  • 21. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study.
    Nilamsari WP; Rizqi MF; Regina NO; Wulaningrum PA; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):783-787. PubMed ID: 34214373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
    Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
    Chung SJ; Byeon SJ; Choi JH
    J Korean Med Sci; 2022 Apr; 37(16):e128. PubMed ID: 35470602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers.
    Sahu RK; Singh K; Subodh S
    Curr Drug Metab; 2015; 16(7):538-52. PubMed ID: 26264201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability profile of second-line anti-tuberculosis medications.
    Ramachandran G; Swaminathan S
    Drug Saf; 2015 Mar; 38(3):253-69. PubMed ID: 25676682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
    Marra F; Marra CA; Bruchet N; Richardson K; Moadebi S; Elwood RK; Fitzgerald JM
    Int J Tuberc Lung Dis; 2007 Aug; 11(8):868-75. PubMed ID: 17705952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens.
    Noeske J; Nguenko PN
    Trans R Soc Trop Med Hyg; 2002; 96(4):429-33. PubMed ID: 12497982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
    Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
    BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Second-line Medications and Treatment Outcomes in Children With Tuberculosis in a Single Center From 2007 to 2018.
    Chiappini E; Matucci T; Lisi C; Petrolini C; Venturini E; Tersigni C; de Martino M; Galli L
    Pediatr Infect Dis J; 2019 Oct; 38(10):1027-1034. PubMed ID: 31397749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study.
    Massud A; Syed Sulaiman SA; Ahmad N; Shafqat M; Chiau Ming L; Khan AH
    Front Pharmacol; 2022; 13():883483. PubMed ID: 35747749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.
    Cox H; Ford N
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):447-54. PubMed ID: 22325685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.